Introduction: Pre-transplant screening for latent tuberculosis infection (LTBI) is a
| QFT
Before October 21, 2013, QFT was sent out to a local reference lab. After October 31, 2013, testing was performed in-house in accordance with the manufacturer's recommendations (QFT, Cellestis). One milliliter of blood taken from the patient was directly placed into 3 blood collection tubes. One tube contained heparin alone (negative control or nil tube); another contained heparin, dextrose, and phytohemaglutinin (positive control or mitogen tube); and the third contained Mycobacterium tuberculosisspecific antigens ESAT-6, CFP-10, and TB7.7 (the TB antigen tube).
After the tubes were filled, they were shaken 10 times and transferred to an incubator within 16 hours. Tubes were incubated at 37°C upright for 16-24 hours. Before centrifugation and after incubation, tubes may have been held between 4°C and 27°C for up to 3 days. Samples underwent centrifugation and plasma was harvested and tested by enzyme-linked immunosorbent assay to assess the concentration IFN-γ. The difference in IFN-γ concentration from antigen stimulated plasma minus the IFN-γ concentration from plasma incubated without antigen was calculated to assess response. Tests were interpreted in accordance with the manufacturer's specifications.
| Statistical analysis
Baseline characteristics of this cohort were compared by QFT result (positive, negative, or indeterminate) using the Wilcoxon test for continuous variables (age, absolute lymphocyte count) and the chisquare test. Similar comparisons were performed in the same cohort between patients who developed active TB with those who did not.
Using significant predictors from our comparisons by QFT result, we then fit a multivariable logistic regression to evaluate predictors of an indeterminate result. The factors we included in this model were age, gender, MELD, non-US born status, HCV, chronic kidney diseases, hepatocellular carcinoma, inpatient during test, test done at internal lab, absolute lymphocyte count, and lung imaging. An incidence rate for TB among transplant recipients was calculated using the following formula: (number of TB cases 2010-2014 in recipients/ number of transplants 2010-2014) × 100,000 to estimate a rate per 100 000 transplant cases. All statistical analyses were performed using STATA 13 (Stata Corporation, College Station, TX, USA). The institutional review board of the Icahn School of Medicine permitted this research. (Table 1 ; P = .002), have a MELD score >25 (P < .001), have chronic kidney disease (P = .004), and be hospitalized during time of testing (P < .001). Indeterminate test results were also more common when testing was performed at our institution during that time period (not sent to a reference lab). Patients with a positive test had higher rates of hepatitis C (P = .003) and hepatocellular carcinoma (P = .003) as well as higher median absolute lymphocyte counts (P = .03) and chest imaging with evidence of prior granulomatous disease (P < .001). In the multivariate analysis ( Overall, the active TB incidence rate among LTR in our institution was 1102/100 000. No patient who developed post-transplant active TB had a positive QFT screening test prior to transplant (Table 2) . Pulmonary disease was the most common manifestation of active TB. Patients who developed TB after transplant were all born outside of the United States (P = .06), had higher rates of nonalcoholic steatohepatitis (P = .01), and chest imaging with evidence of prior granulomatous disease (P = .006) ( Table 3 ).
| RE SULTS

| D ISCUSS I ON
Active TB is a feared complication of organ transplantation. In our retrospective cohort of LTR who underwent pre-transplant LTBI testing, we found high rates of indeterminate test results and QFT was a poor predictor of active TB. Our experience further highlights the challenges of LTBI assessment in LTR.
Though the rate of active TB in the United States is 3.0 cases per 100 000 persons (3.0/100 000) in certain New York City neighborhoods, it is as high as 18.2/100 000 inhabitants, with 82% of cases from 2015 occurring among foreign-born patients. 10 Rates of active TB in SOT recipients are significantly higher with estimates in US LTR of 85/100 000 and SOT recipients in other countries as high as 512/100 000. 7, 11 In our population of pre-transplant candidates screened, we found a post-transplant, active TB rate of 1102/100 000. This is likely a result of the diverse patient population served by our institution and the TB rates in the surrounding communities. All 4 patients who developed active TB after transplant were from TB-endemic regions outside of the continental United States.
No patients reported prior positive TB exposures, and no patient revisited an endemic area after LTBI testing was performed. However, when compared with those patients who did not develop TB, there was no significant difference in non-US status. Similar to reports from endemic areas, 12 we found that LTRs with radiologic features of prior TB were at higher risk of developing active TB after transplant.
Though computed tomography (CT) of the chest was not routine in the screening of our candidates, this approach has been suggested to be more useful in LT candidates in an endemic area with CT abnormalities observed in patients with a negative chest x-ray. 13 Of the 4 patients who developed post-transplant TB, 3 had negative QFT QFT appears to be a poor predictor of progression to active TB. 18 Though no study has directly evaluated this mechanism, the multi- The effects of the lymphocyte count on the mitogen response have been well described. 20 Previous studies have found lower lymphocyte counts to be associated with indeterminate results, 17 yet in our group of patients, there was no significant association (P = .7).
However, patients with a positive QFT test had higher median absolute lymphocyte counts. Further, patients with prior granulomatous disease seen on chest imaging were also more likely to have a positive QFT result (P < .001). These associations are consistent with previous literature in immunocompetent and immunocompromised hosts. 21 When testing was done at our on-site lab, there was a higher rate of indeterminate test results. The nuances of IGRA testing are significant, and blood volume, tube shaking, prolonged incubation time, and incubation delay have all been recognized to effect the result and its reproducibility. 22 Our lab has evaluated testing during this time and found that after bringing the testing in-house, there were prolonged incubation times up to 3 hours over the limit specified in the package insert. The overall indeterminate rate for non-immunosuppressed patients was low (<5%) and comparable between the reference lab and the in-house lab. Nevertheless, the workflow was changed in 2015 to decrease incubation time and include more frequent specimen centrifugation.
It is possible that immunocompromised patient samples are more sensitive to changes in testing parameters than "healthy" non- Our study has several limitations. As we did not screen all candidates prior to liver transplant, we may have introduced selection bias into our analysis of test characteristics. Further, the small numbers of TB cases in our patient cohort markedly limited our ability to identify unique characteristics of patients who developed active TB.
In addition, this study relied on retrospective clinical data; therefore, there is a chance that some cases of active TB may have been missed, although transplant programs tend to retain their patients and are, therefore, likely to have good ascertainment of these outcomes.
| CON CLUS ION
In summary, our experience further demonstrates that IGRA testing may have poor sensitivity and limited specificity in patients with end-stage liver disease and may be a poor predictor of active TB after transplant. Providers should also be aware of the challenges related to reproducibility and lab variability. Careful protocols should be created for TB screening prior to liver transplant in centers with large populations of patients from TB-endemic areas to ensure appropriate screening, treatment, and follow-up. In addition, candidates with liver disease should be screened for LTBI as early as possible in the evaluation process considering poor test performance in patients with high MELD scores. Given the difficulties of testing, diligent risk factor assessment and CT chest should be considered as part of the screening process in centers with large foreign-born populations.
Additional testing for these patients (TST or T-SPOT) may also be warranted in this high-risk population. Centers in the United States with large foreign-born populations should carefully consider treating high-risk patients with abnormal lung imaging regardless of LTBI testing result. 
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